Chen Hsin-Hung, Riva-Cambrin Jay, Brockmeyer Douglas L, Walker Marion L, Kestle John R W
Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taiwan, Republic of China.
J Neurosurg Pediatr. 2011 Apr;7(4):408-12. doi: 10.3171/2011.1.PEDS10389.
In late 2008, the authors recognized a new type of ventriculoperitoneal shunt failure specific to the Bio-Glide Snap Shunt ventricular catheters. This prompted a retrospective review of the patient cohort and resulted in a recall by the FDA in the US.
After the index cases were identified, the FDA was notified by the hospital, leading to a recall of the product. Hospital operative logs were used to identify patients in whom the affected products were used. A letter describing the risk was sent to all patients offering a free screening CT scan to look for disconnection. A call center was established to respond to patient questions, and an informational video was made available on the hospital website. The authors reviewed the records of the index cases and other cases subsequently identified.
Seven index cases and an additional 16 cases of disconnection were identified in the 466 patients in whom a BioGlide Snap Shunt ventricular catheter had been implanted. Mean time to disconnection was 2.7 years (range 4 days-5.8 years). Computed tomography slices in the plane of the catheter helped visualize disconnections. Retrieval was difficult, and in 5 patients the disconnected catheter was not removable. Three catheters were completely within the ventricle. At presentation, 4 children suffered from severe neurological deficits, including one who died as a result of the shunt malfunction.
BioGlide snap-design ventricular catheters are prone to disconnection. Continued vigilance and specific imaging are important. Catheter removal after disconnection may be difficult. Elective removal prior to disconnection in asymptomatic children has not been performed.
2008年末,作者们认识到一种特定于Bio-Glide Snap分流管脑室导管的新型脑室-腹腔分流失败类型。这促使对患者队列进行回顾性研究,并导致美国食品药品监督管理局(FDA)召回该产品。
在确定索引病例后,医院通知了FDA,导致该产品被召回。利用医院手术记录来识别使用了受影响产品的患者。向所有患者发送了一封描述风险的信,提供免费的筛查CT扫描以查找分流管断开情况。设立了一个呼叫中心来回答患者的问题,并在医院网站上提供了一个信息视频。作者们回顾了索引病例以及随后确定的其他病例的记录。
在植入了BioGlide Snap分流管脑室导管的466例患者中,确定了7例索引病例以及另外16例分流管断开病例。分流管断开的平均时间为2.7年(范围4天至5.8年)。导管平面的计算机断层扫描切片有助于观察到分流管断开情况。取出分流管很困难,5例患者中,断开的导管无法取出。3根导管完全位于脑室内。就诊时,4名儿童出现严重神经功能缺损,其中1名因分流管故障死亡。
BioGlide卡扣式设计的脑室导管易于断开。持续的警惕性和特定的影像学检查很重要。分流管断开后取出可能困难。对于无症状儿童,在分流管断开前进行选择性取出尚未实施。